Drug

Paramethadione

As of the edition of 20 October 2026, Paramethadione is a small molecule: marketed, first approved in 1982 (US); acts on CACNA1G, CACNA1H and CACNA1I; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1982
Kind
Small molecule
Brand name
Paradione
First approved
1 January 1982 (US)
Approvals on record
3 in 1 region
Holder of the most recent approval
AbbVie

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Companies that need a new molecule because of this drug

1 company-target row on route A because of this drug.

Companies on route A for this drug

In the product

1 company-target row is on route A because of Paramethadione.

Targets

GeneProteinUniProt
CACNA1GVoltage-dependent T-type calcium channel subunit alpha-1GO43497
CACNA1HVoltage-dependent T-type calcium channel subunit alpha-1HO95180
CACNA1IVoltage-dependent T-type calcium channel subunit alpha-1IQ9P0X4

Who has held its approvals

CompanyRoleYears
AbbVieAcquired holder2012 to now
AbbottEarlier holder